Skip NavigationSkip to Content
Return Return to Search Results

Deubiquitinating enzyme VCIP135 dictates the duration of botulinum neurotoxin type A intoxication.

  1. Author:
    Tsai, Yien Che
    Kotiya, Archana
    Kiris, Erkan
    Yang, Mei
    Bavari, Sina
    Tessarollo, Lino
    Oyler, George A
    Weissman, Allan

  2. Author Address

    Laboratory of Protein Dynamics and Signaling, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702; weissmaa@mail.nih.gov tsaiyien@mail.nih.gov., Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD 21218., Synaptic Research LLC, Halethorpe, MD 21227., US Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702., Mouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702., Laboratory of Protein Dynamics and Signaling, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702.,
    1. Year: 2017
    2. Date: Jun 27
    3. Epub Date: 2017 Jun 05
  2. Journal: Proceedings of the National Academy of Sciences of the United States of America
    1. 114
    2. 26
    3. Pages: E5158-E5166
  4. Type of Article: Article
  5. ISSN: 0027-8424
  1. Abstract:

    Botulism is characterized by flaccid paralysis, which can be caused by intoxication with any of the seven known serotypes of botulinum neurotoxin (BoNT), all of which disrupt synaptic transmission by endoproteolytic cleavage of SNARE proteins. BoNT serotype A (BoNT/A) has the most prolonged or persistent effects, which can last several months, and exerts its effects by specifically cleaving and inactivating SNAP25. A major factor contributing to the persistence of intoxication is the long half-life of the catalytic light chain, which remains enzymatically active months after entry into cells. Here we report that BoNT/A catalytic light chain binds to, and is a substrate for, the ubiquitin ligase HECTD2. However, the light chain evades proteasomal degradation by the dominant effect of a deubiquitinating enzyme, VCIP135/VCPIP1. This deubiquitinating enzyme binds BoNT/A light chain directly, with the two associating in cells through the C-terminal 77 amino acids of the light chain protease. The development of specific DUB inhibitors, together with inhibitors of BoNT/A proteolytic activity, may be useful for reducing the morbidity and public health costs associated with BoNT/A intoxication and could have potential biodefense implications.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1073/pnas.1621076114
  3. PMID: 28584101
  4. View record in Web of Science®
  5. WOS: 000404108400019

Library Notes

  1. Fiscal Year: FY2016-2017
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel